資料載入中.....
|
請使用永久網址來引用或連結此文件:
http://libir.tmu.edu.tw/handle/987654321/65324
|
| 題名: | ABL genomic editing sufficiently abolishes oncogenesis of human chronic myeloid leukemia cells in vitro and in vivo. |
| 作者: | 李嘉華
Shu-Huey Chen, Yao-Yu Hsieh, Huey-En Tzeng, Chun-Yu Lin, Kai-Wen Hsu, Yun-Shan Chiang, Su-Mei Lin, Ming-Jang Su, Wen-Shyang Hsieh, Chia-Hwa Lee |
| 貢獻者: | 醫學檢驗暨生物技術學系 |
| 日期: | 2020-05 |
| 上傳時間: | 2025-03-31 10:51:50 (UTC+8) |
| 摘要: | Abstract
Chronic myelogenous leukemia (CML) is the most common type of leukemia in adults, and more than 90% of CML patients harbor the abnormal Philadelphia chromosome (Ph) that encodes the BCR-ABL oncoprotein. Although the ABL kinase inhibitor (imatinib) has proven to be very effective in achieving high remission rates and improving prognosis, up to 33% of CML patients still cannot achieve an optimal response. Here, we used CRISPR/Cas9 to specifically target the BCR-ABL junction region in K562 cells, resulting in the inhibition of cancer cell growth and oncogenesis. Due to the variety of BCR-ABL junctions in CML patients, we utilized gene editing of the human ABL gene for clinical applications. Using the ABL gene-edited virus in K562 cells, we detected 41.2% indels in ABL sgRNA_2-infected cells. The ABL-edited cells reveled significant suppression of BCR-ABL protein expression and downstream signals, inhibiting cell growth and increasing cell apoptosis. Next, we introduced the ABL gene-edited virus into a systemic K562 leukemia xenograft mouse model, and bioluminescence imaging of the mice showed a significant reduction in the leukemia cell population in ABL-targeted mice, compared to the scramble sgRNA virus-injected mice. In CML cells from clinical samples, infection with the ABL gene-edited virus resulted in more than 30.9% indels and significant cancer cell death. Notably, no off-target effects or bone marrow cell suppression was found using the ABL gene-edited virus, ensuring both user safety and treatment efficacy. This study demonstrated the critical role of the ABL gene in maintaining CML cell survival and tumorigenicity in vitro and in vivo. ABL gene editing-based therapy might provide a potential strategy for imatinib-insensitive or resistant CML patients. |
| 關聯: | Cancers (Basel). 2020 May 29; 12(6): 1399 |
| 描述: | 【111-1 升等】臺北醫學大學教師升等專門著作
職別：兼任
送審等級：教授
著作送審 |
| 資料類型: | article |
| 顯示於類別: | [教師升等送審著作] 111
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 1 | 檢視/開啟 |
|
在TMUIR中所有的資料項目都受到原著作權保護.
|
